You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 273 No. 12, March 22, 1995 TABLE OF CONTENTS
  JAMA
  •  Online Features
  ARTICLE
 This Article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA

Costs and effects of long-term oral anticoagulant treatment after myocardial infarction

P. F. van Bergen, J. J. Jonker, B. A. van Hout, R. T. van Domburg, J. W. Deckers, A. J. Azar and A. Hofman
ASPECT Coordinating Centre, Rotterdam, The Netherlands.

OBJECTIVE--To investigate the costs and effects of long-term oral anticoagulant treatment after myocardial infarction. DESIGN--Cost-effectiveness analysis, based on a randomized, double-blind, placebo-controlled trial. SETTING--Sixty Dutch hospitals. PATIENTS--A total of 3404 hospital survivors of acute myocardial infarction randomized within a median period of 4 days after discharge to either oral anticoagulant treatment or placebo. The mean follow-up was 37 months. INTERVENTION--Oral anticoagulant treatment aimed at a target international normalized ratio of 2.8 to 4.8. MAIN OUTCOME MEASUREMENTS--Costs of hospital stay during readmissions, costs related to major cardiologic interventions, and costs of oral anticoagulant treatment. RESULTS--The costs of oral anticoagulant treatment were estimated at 394 Dutch guilders (Dfl) per patient-year (Dfl 1 = US $0.58). Placebo patients stayed 18,830 days in the hospital compared with 15,083 days for anticoagulation patients. Average costs per patient of medical care during follow-up were estimated at Dfl 10,784 for placebo patients and Dfl 9878 for anticoagulation patients. CONCLUSIONS--Costs of long-term anticoagulant treatment are outweighed by the costs of prevented clinical events.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Renal Artery Stenosis: Cost-effectiveness of Diagnosis and Treatment
van Helvoort-Postulart et al.
Radiology 2007;244:505-513.
ABSTRACT | FULL TEXT  

Economic factors associated with antithrombotic treatments for stroke prevention in patients with atrial fibrillation
Miller et al.
Eur Heart J Suppl 2005;7:C41-C54.
ABSTRACT | FULL TEXT  

State-of-the-Art Review : Secondary Prevention of Myocardial Infarction: Beneficial Effect of Combining Oral Anticoagulant Plus Aspirin: Therapy Based on Evidence
Altman et al.
CLIN APPL THROMB HEMOST 2000;6:126-134.
 

Anticoagulation Reduces Costs and Time in Hospital After MI
Journal Watch Cardiology 1995;1995:18-18.
FULL TEXT  

ANTICOAGULATION SAVES COSTS AFTER MI
JWatch General 1995;1995:2-2.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1995 American Medical Association. All Rights Reserved.